C9 complement inhibitor

Details C9 complement inhibitor C9 complement inhibitor

1995-11-15

1998-12-01

Feisee, Lila

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

530324, 5303871, 5303872, 4241311, 4241381, A01N 100, A61K 3800, A61K 39395, C07K 1600

Patent

active

058438840

ABSTRACT:
Pharmaceutical compositions are designed based on the criticality of a portion of C9 for assembly of the C5b9 complex, which specifically modulate binding of CD59 to C9, either molecules structurally mimicking C9 amino acid residues 359 to 384 which bind to CD59 or molecules binding to C9 amino acid residues 359 to 384. Molecules which inhibit CD59 binding include peptides containing residues 359-384 which compete for binding with the other components of the C5b9 complex and anti-idiotypic antibodies immunoreactive with C9 amino acid residues 359 to 384. Molecules which prevent assembly of the C5b-9 complex include antibodies and antibody fragments immunoreactive with amino acid residues 359 to 384 of C9, peptides that bind to amino acid residues 359 to 384 of C9, and nucleotide molecules that bind to amino acid residues 359 to 384 of C9.

REFERENCES:
patent: 3625214 (1971-12-01), Higuchi
patent: 4244946 (1981-01-01), Rivier et al.
patent: 4305872 (1981-12-01), Johnston et al.
patent: 4316891 (1982-02-01), Guillemin et al.
patent: 4629784 (1986-12-01), Stammer
patent: 4789734 (1988-12-01), Pierschbacher
patent: 4792525 (1988-12-01), Ruoslaghti et al.
patent: 4906474 (1990-03-01), Langer et al.
patent: 4925673 (1990-05-01), Steiner et al.
Agrawal, et al., "Oligodeoxynuleoside Phosphoramidates And As Inhibitors of Human Immunodeficiency Virus, "Proc. Natl. Acad. Sci. USA, 85:7079-7083 (1988).
Askew, et al,J. Am. Chem. Soc.,111:1082-1090 (1989).
Chang, et al., "Identity of a Peptide Domain of Human C9 That Is Bound by the Cell-surface Complement Inhibitor, CD59",J. Bio. Chem., 269 (42):26424-26430 (1994).
Clackson, et al., Nature, 352:624-688 (1991).
Daugherty, et al., Nucl. Acids Res., 19:2471-2476 (1991).
Davies, et al., J. Exp. Med.,170:637-654 (1989).
Davies, et al., Immunol. Res.,12:258-275 (1993)
Dupuis, et al., Mol. Immunol.,30:95-100 (1993)
Gregoriadis, Chapter 14. "Liposomes", Drug Carriers in Biology and Medicine, 287-341 (Academic Press, 1979).
Hamilton, et al., "Regulatory Control of the Terminal Complement Proteins at the Surface of Human Endothelial Cells: Neutralization of a C5b-9 Inhibitor by Antibody to CD59" Blood,76:2572-2577 (1990).
Hamilton, et al., "Complement Proteins C5b-9 Induce Vesiculation of the Endothelial Plasma Membrane and Expose Catalytic Surface for Assembly of the Prothrombinase Enzyme Complex " J. Bio. Chem., 265:3809-3814 (1990).
Harada, et al., J. Oral Pathol. Med.(Denmark), 22(f):145-152 (1993).
Hatanaka, et al.,Biochim. Biophys. Acta Protein Struct. Mol. Enzymol. 1209:117-122 (1994).
Hattori, et al., "Stimulated Secretion of Endothelial von Willebrand Factor Is Accompanied by Rapid Redistribution to the Cell Surface of the Intracellular Granule Membrane Protein GMP-140" J. Bio. Chem., 264(14):7768-7771 (1989).
Holguin, et al., J. Clin. Invest., 84:7-17 (1989).
Husler, et al., "Chimeras of Human Complement C9 Reveal the site Recognized by Complement Regulatory Protein CD59", J. Biol. Chem., 270(8):3438-3486 (1995).
Husler, et al., "Role of a Disulfide-bonded Peptide Loop within Human Complement C9 in the species-Selectivity of Complement Inhibitor CD59", Biochem., 35(10):3263-3269 (1996).
Itakura, et al., in Ann. Rev. Biochem., 1984 53:323-356 (1984).
Inai, et al., Histochemistry (German), 99(5):335-362 (1993).
Kabat, et al., Sequences of Proteins of Immunlogical Interest, 4th Ed. (U.S. Dept. Health and Human Services, Bethesda, MD, 1987).
Lewis & Dean, Proc. R. Soc. Lond., 236:125-140 and (1989) 141-162.
Lublin & Atkinson,Current Topics Microbio. Immunol., 153:123-145 (1989).
Maher, et al., (1989).
McKinaly & Rossman, Annu. Rev. Pharmacol. Toxicol., 29:111-122 (1989).
Medof, et al., J. Exp. Med. 160:1558-1578 (1984).
Merrifield, J. Am. Chem. Soc., 85:2149-2154 (1964).
Mulder, et al., Hum. Immunol., 36(3):186-192 (1993).
Narang, et al., in Methods Enzymol., 65:610-620 (1980).
Ninomiya & Sims, "Contribution of the N-Linked Carbohydrate of Erythrocyte Antigen CD59 to Its Complement-inhibitory Activity ", J. Biol. Chem.,267(12):8404-8410 (1992).
Ninomiya & Sims, "The Human Complement Regulatory Protein CD59 Binds to the .alpha.-Chain of C8 and to the Domain of C9", J. Bio. Chem. , 267(19):13675-13680 (1992).
Offensperger, et al., EMBO J., 12:1257-1262 (1993).
Perry & Davies, QSAR: Quantitative Structure-Activity Relationships in Drug Design pp. 189-193 (Alan R. Liss, inc. 1989).
Ripka, New Scientist, 54-57 (Jun. 16, 1988).
Rollins, et al., "Inhibition of Homologous Complement by CD59 is Mediated by a Species-Selective Recognition Conferred Through Binding to C8 Within C5b-8 or C9 Within C5b-9.sup.1 ", J. Immunol., 146:2345-2351 (1991).
Rollins & Sims, "The Complement-Inhibitory Activity of CD59 Resides In Its Capacity to Block Incorporation of C9 Into Membrane C5b-9 .sup.1 ",J. Immunol., 144:3478-3483 (1990).
Rotivinen, et al.,Acta Pharmaceutica Fennica,97:159-166 (198).
Sambrook, et al., Chapters 5, 6) to purely synthetic methods for example, by the cyanoethy phosphoramidite method using a Milligen or Beckman System 1Plus DNA synthesizer.
Sarin, et al., Proc. Natl. Acad. Sci. USA, 85:7448-7794 (1989).
Schaller, et al. J. Protein Chem., 13:472-473 (1994).
Schonermark, et al. ,J. Immunol., 136:1772-1776 (1986).
Shaw, et al.,Nucleic Acids Res, 19:747-750 (1991).
Sims, "Interaction of Human Platelets with the Complement System ",Platelet Immunobiology, Chapter 18, 354-383 (1990).
Sims, et al., "Regulatory Control of Complement on Blood Platelets, " J. Biol. Chem., 264:19228-19235 (1989).
Stauber, et al., J. Immunol. Methods (Netherlands), 161(2):157-168 (1993).
Sugita, et al., J. Biochem.(Tokyo), 104:633-637 (1988).
Szostak,TIBS,19:89 (1992).
Venkateswaran, et al.,Hybridoma,11(6)729-739 (1992).
Wiedmer & Sims, "Cyanine Dye Fluorescence Used to Measure Membrane Potential Changes due to the Assembly of Complement Proteins C5b-9 ", J. Membr. Biol.,84:249-258 (1985).
Wiedmar & Sims, "Effect of Complement Proteins C5b-9 on Blood Platelets ", J. Bio. Chem., 260(13):8014-8019 (1985).
Zalman, et al., Proc. Natl. Acad. Sci., U.S.A.,83:6975-6979 (1986).
Burgess et al. (J. Cell Bio. 111:2129-2138) 1990.
Lazar et al (Mol +Cell Bio, 8:1247-1252) 1988.
Tao et al., (J. Immunol, 143:2595-2601 1989.
Stanley et al (EMBO J. 4:375-382, 1985).

Affiliated with

Also associated with

Rating

C9 complement inhibitor does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with C9 complement inhibitor, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and C9 complement inhibitor will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2395621